SCHEMBL17795259

SCHEMBL17795259

Cc1ccc(-c2cncc(S(C)(=O)=O)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 7/20 0.52
PIK3CD O00329 3/20 0.52
PIK3CA P42336 3/20 0.52
PIK3CB P42338 2/20 0.52
PI4KA P42356 1/20 0.52
PI4KB Q9UBF8 1/20 0.52
PIK3C3 Q8NEB9 1/20 0.49
PTGS2 P35354 7/20 0.47
PRMT5 O14744 1/20 0.47
WDR77 Q9BQA1 1/20 0.47
GPR55 Q9Y2T6 2/20 0.46
MAOA P21397 2/20 0.45
MAOB P27338 2/20 0.45
LOXL2 Q9Y4K0 2/20 0.45
KCNH2 Q12809 1/20 0.45
AOC3 Q16853 1/20 0.45
PTGS1 P23219 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5700416 0.84 PIK3CG (0.50) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL17806575 0.81 PIK3CG (0.49) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL21753325 0.81 PIK3CG (0.49) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL21753374 0.80 PIK3CG (0.48) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL21753363 0.80 PTGS2 (0.50) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL2762071 0.77 PIK3CG (0.54) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL1641957 0.77 PTGS2 (0.44) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL12341698 0.76 PTGS2 (0.68) PTGS2PTGS1
SCHEMBL11992474 0.75 PTGS2 (0.48) PIK3CGPIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL28844052 0.74 MAOA (0.60) MAOAMAOBLOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
WO-2016086200-A9 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH, INC. (US) 2016-06-23 WO disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed
WO-2016086200-A1 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH, INC. (US) 2016-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 PIK3CG 3384/4885PIK3CD 3096/4885PIK3CA 2649/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 PIK3CG 3384/4885PIK3CD 3096/4885PIK3CA 2649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.